Spilios V. Argyropoulos

2.1k total citations
28 papers, 1.5k citations indexed

About

Spilios V. Argyropoulos is a scholar working on Experimental and Cognitive Psychology, Pharmacology and Clinical Psychology. According to data from OpenAlex, Spilios V. Argyropoulos has authored 28 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Experimental and Cognitive Psychology, 11 papers in Pharmacology and 7 papers in Clinical Psychology. Recurrent topics in Spilios V. Argyropoulos's work include Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (20 papers), Treatment of Major Depression (11 papers) and Mental Health Research Topics (6 papers). Spilios V. Argyropoulos is often cited by papers focused on Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (20 papers), Treatment of Major Depression (11 papers) and Mental Health Research Topics (6 papers). Spilios V. Argyropoulos collaborates with scholars based in United Kingdom, Australia and New Zealand. Spilios V. Argyropoulos's co-authors include David Nutt, Sue Wilson, John Sandford, Jon Nash, Caroline Bell, Sean Hood, Anthony S. Hale, Paul Willner, Ann Rich and John Potokar and has published in prestigious journals such as Biological Psychiatry, The British Journal of Psychiatry and Pharmacology & Therapeutics.

In The Last Decade

Spilios V. Argyropoulos

27 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Spilios V. Argyropoulos United Kingdom 17 739 528 366 253 236 28 1.5k
G.S.F. Ruigt Netherlands 25 324 0.4× 917 1.7× 646 1.8× 284 1.1× 145 0.6× 49 2.1k
Ulrich Hemmeter Switzerland 18 443 0.6× 509 1.0× 162 0.4× 148 0.6× 93 0.4× 77 1.3k
Darragh Downey United Kingdom 20 399 0.5× 548 1.0× 191 0.5× 349 1.4× 292 1.2× 33 1.4k
J. Mendlewicz Belgium 25 603 0.8× 485 0.9× 344 0.9× 452 1.8× 448 1.9× 69 2.4k
Emma Childs United States 26 324 0.4× 338 0.6× 443 1.2× 534 2.1× 456 1.9× 38 2.0k
G Darcourt France 22 506 0.7× 445 0.8× 148 0.4× 174 0.7× 243 1.0× 83 1.7k
Peter Manza United States 25 423 0.6× 1.0k 1.9× 432 1.2× 267 1.1× 222 0.9× 96 2.3k
José Francisco Navarro Spain 23 247 0.3× 252 0.5× 664 1.8× 131 0.5× 323 1.4× 141 1.5k
Arnd Barocka Germany 17 531 0.7× 386 0.7× 154 0.4× 603 2.4× 224 0.9× 34 1.5k
William Pitchot Belgium 22 241 0.3× 282 0.5× 266 0.7× 189 0.7× 454 1.9× 107 1.5k

Countries citing papers authored by Spilios V. Argyropoulos

Since Specialization
Citations

This map shows the geographic impact of Spilios V. Argyropoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Spilios V. Argyropoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Spilios V. Argyropoulos more than expected).

Fields of papers citing papers by Spilios V. Argyropoulos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Spilios V. Argyropoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Spilios V. Argyropoulos. The network helps show where Spilios V. Argyropoulos may publish in the future.

Co-authorship network of co-authors of Spilios V. Argyropoulos

This figure shows the co-authorship network connecting the top 25 collaborators of Spilios V. Argyropoulos. A scholar is included among the top collaborators of Spilios V. Argyropoulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Spilios V. Argyropoulos. Spilios V. Argyropoulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Argyropoulos, Spilios V., et al.. (2009). Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone. Journal of Sleep Research. 18(3). 342–348. 15 indexed citations
2.
Bell, Caroline, Sean Hood, John Potokar, et al.. (2009). Rapid tryptophan depletion following cognitive behavioural therapy for panic disorder. Psychopharmacology. 213(2-3). 593–602. 7 indexed citations
3.
Hood, Sean, Dana Hince, Simon Davies, et al.. (2009). Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. Psychopharmacology. 208(2). 223–232. 18 indexed citations
4.
Nash, Jon, Peter A. Sargent, Eugenii A. Rabiner, et al.. (2008). Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. The British Journal of Psychiatry. 193(3). 229–234. 131 indexed citations
5.
Argyropoulos, Spilios V., George B. Ploubidis, Marisha E. Palm, et al.. (2007). Development and validation of the Generalized Anxiety Disorder Inventory (GADI). Journal of Psychopharmacology. 21(2). 145–152. 26 indexed citations
6.
Davies, Simon, Sean Hood, Spilios V. Argyropoulos, et al.. (2006). Depleting Serotonin Enhances Both Cardiovascular and Psychological Stress Reactivity in Recovered Patients With Anxiety Disorders. Journal of Clinical Psychopharmacology. 26(4). 414–418. 43 indexed citations
7.
Wilson, Sue & Spilios V. Argyropoulos. (2005). Antidepressants and Sleep. Drugs. 65(7). 927–947. 256 indexed citations
8.
Argyropoulos, Spilios V. & Sue Wilson. (2005). Sleep disturbances in depression and the effects of antidepressants. International Review of Psychiatry. 17(4). 237–245. 85 indexed citations
9.
Willner, Paul, Anthony S. Hale, & Spilios V. Argyropoulos. (2005). Dopaminergic mechanism of antidepressant action in depressed patients. Journal of Affective Disorders. 86(1). 37–45. 137 indexed citations
10.
Bailey, Jayne, Spilios V. Argyropoulos, Adrian Kendrick, & David Nutt. (2005). Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers. Depression and Anxiety. 21(1). 18–25. 94 indexed citations
11.
Argyropoulos, Spilios V. & Sophia Frangou. (2004). Pharmacological treatment of bipolar disorder. Psychiatry. 3(7). 34–37.
12.
Argyropoulos, Spilios V., Sean Hood, Caroline Bell, et al.. (2004). Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biological Psychiatry. 56(7). 503–509. 69 indexed citations
13.
Argyropoulos, Spilios V., Jane Hicks, Jon Nash, et al.. (2003). Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. Psychiatry Research. 120(2). 179–190. 97 indexed citations
14.
Hicks, Jane, Spilios V. Argyropoulos, Ann Rich, et al.. (2002). Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. The British Journal of Psychiatry. 180(6). 528–535. 62 indexed citations
15.
Argyropoulos, Spilios V., et al.. (2002). Venlafaxine: a new class of antidepressant. Hospital Medicine. 63(9). 549–552. 4 indexed citations
16.
Argyropoulos, Spilios V.. (2002). Inhalation of 35% CO2 results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology. 27(6). 715–729. 81 indexed citations
17.
Argyropoulos, Spilios V., Caroline Bell, & David Nutt. (2001). BRAIN FUNCTION IN SOCIAL ANXIETY DISORDER. Psychiatric Clinics of North America. 24(4). 707–722. 22 indexed citations
18.
Sandford, John, Spilios V. Argyropoulos, & David Nutt. (2000). The psychobiology of anxiolytic drugs. Pharmacology & Therapeutics. 88(3). 197–212. 93 indexed citations
19.
Argyropoulos, Spilios V., John Sandford, & David Nutt. (2000). The psychobiology of anxiolytic drugs. Pharmacology & Therapeutics. 88(3). 213–227. 89 indexed citations
20.
Nutt, David, et al.. (1998). Generalized anxiety disorder : diagnosis, treatment and its relationship to other anxiety disorders. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G.S.F. Ruigt Breakdown of academic impact, for papers by Ulrich Hemmeter Breakdown of academic impact, for papers by Darragh Downey Breakdown of academic impact, for papers by J. Mendlewicz Breakdown of academic impact, for papers by Emma Childs Breakdown of academic impact, for papers by G Darcourt Breakdown of academic impact, for papers by Peter Manza Breakdown of academic impact, for papers by José Francisco Navarro Breakdown of academic impact, for papers by Arnd Barocka Breakdown of academic impact, for papers by William Pitchot
Rankless by CCL
2026